Browse BCL11B

Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain -
Function

Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes (PubMed:16809611). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity).

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0002064 epithelial cell development
GO:0002200 somatic diversification of immune receptors
GO:0002521 leukocyte differentiation
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002568 somatic diversification of T cell receptor genes
GO:0002681 somatic recombination of T cell receptor gene segments
GO:0003334 keratinocyte development
GO:0003382 epithelial cell morphogenesis
GO:0006310 DNA recombination
GO:0007159 leukocyte cell-cell adhesion
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007423 sensory organ development
GO:0008544 epidermis development
GO:0009791 post-embryonic development
GO:0009913 epidermal cell differentiation
GO:0010837 regulation of keratinocyte proliferation
GO:0016444 somatic cell DNA recombination
GO:0019216 regulation of lipid metabolic process
GO:0021537 telencephalon development
GO:0021544 subpallium development
GO:0021756 striatum development
GO:0021773 striatal medium spiny neuron differentiation
GO:0021872 forebrain generation of neurons
GO:0021877 forebrain neuron fate commitment
GO:0021879 forebrain neuron differentiation
GO:0021902 commitment of neuronal cell to specific neuron type in forebrain
GO:0021953 central nervous system neuron differentiation
GO:0030098 lymphocyte differentiation
GO:0030216 keratinocyte differentiation
GO:0030217 T cell differentiation
GO:0030900 forebrain development
GO:0031077 post-embryonic camera-type eye development
GO:0033077 T cell differentiation in thymus
GO:0033151 V(D)J recombination
GO:0033153 T cell receptor V(D)J recombination
GO:0042110 T cell activation
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0043010 camera-type eye development
GO:0043368 positive T cell selection
GO:0043588 skin development
GO:0043616 keratinocyte proliferation
GO:0045058 T cell selection
GO:0045165 cell fate commitment
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0048538 thymus development
GO:0048569 post-embryonic animal organ development
GO:0048663 neuron fate commitment
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0061564 axon development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:0071678 olfactory bulb axon guidance
GO:0097485 neuron projection guidance
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BCL11B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BCL11B and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24446520MelanomaInhibit immunityUsing several tumor models, we demonstrate that mice deficient in Bcl11b in T cells, although having reduced numbers of T cells in the peripheral lymphoid organs, developed significantly less tumors compared with wild-type mice. Although the number of myeloid-derived suppressor cells was increased in the lungs with metastatic tumors of Bcl11b(F/F)/CD4-Cre mice, their arginase-1 levels were severely reduced.
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BCL11B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BCL11B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1660.685
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4610.509
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0440.94
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4260.372
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0260.55
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3370.868
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.720.0132
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.3370.0283
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.0210.387
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2180.021
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0510.159
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1840.308
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BCL11B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.57.43.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCL11B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCL11B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCL11B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCL11B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BCL11B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BCL11B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBCL11B
NameB-cell CLL/lymphoma 11B (zinc finger protein)
Aliases CTIP-2; CTIP2; hRIT1-alpha; ZNF856B; ATL1-alpha; ATL1-beta; ATL1-delta; ATL1-gamma; B-cell CLL/lymphoma 11B/ ......
Chromosomal Location14q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BCL11B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.